NATURE’S SUNSHINE PRODUCTS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
NATURE’S SUNSHINE PRODUCTS, INC. (NATR) reported Net Income (Loss) Available to Common Stockholders, Diluted of $3.54 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- NATURE’S SUNSHINE PRODUCTS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $3.54M, a 33.66% decline year-over-year.
- NATURE’S SUNSHINE PRODUCTS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was $5.33M.
- NATURE’S SUNSHINE PRODUCTS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2021-09-30 was $4.86M, a 28.08% decline year-over-year.
- NATURE’S SUNSHINE PRODUCTS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2021-06-30 was $6.54M, a 13.66% increase year-over-year.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month |
|---|---|---|---|
| 2026-06-30 | $3.54M 10-Q · filed 2026-08-06 | $8.66M 10-Q · filed 2026-08-06 | |
| 2025-06-30 | $5.33M 10-Q · filed 2026-08-06 | $10.08M 10-Q · filed 2026-08-06 | |
| 2021-09-30 | $4.86M 10-Q · filed 2021-11-04 | $11.40M derived: sum of 2 quarters · filed 2021-11-04 | $15.41M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $6.54M 10-Q · filed 2021-08-05 | $10.56M 10-Q · filed 2021-08-05 | |
| 2020-09-30 | $6.75M 10-Q · filed 2021-11-04 | $12.51M derived: sum of 2 quarters · filed 2021-11-04 | $15.47M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $5.75M 10-Q · filed 2021-08-05 | $8.72M 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |